Xianjun Yu

ORCID: 0000-0002-6697-7143 · 3 papers in corpus
2025
A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.
Signal transduction and targeted therapy ·doi:10.1038/s41392-025-02530-2

Nab-paclitaxel plus gemcitabine (AG) is the standard first-line chemotherapy for advanced or metastatic pancreatic ductal adenocarcinoma and has limited efficacy. This phase 1b/2 study aimed to evaluate SHR-1701 (an anti-PD-L1/TGF-βRII fusi…

article 2020
Pancréatectomie totale laparoscopique avec conservation de la rate pour TIPMP (avec vidéo)
·doi:10.1016/j.jchirv.2020.05.006
2015
Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.
Medicine ·doi:10.1097/md.0000000000000751

Serum carbohydrate antigen 19-9 (CA19-9) is widely used to predict the prognosis for pancreatic ductal adenocarcinoma (PDAC). However, hyperbilirubinemia and the CA19-9 nonsecretor phenotype restrict the usage of serum CA19-9 alone. The goa…